Huixing Zhou, Yafei Wang, Jiao Chen, Aili He, Jie Jin, Quanyi Lu, Ying Zhao, Junjun Li, Ming Hou, Liping Su, Xun Lai, Wei Wang, Lihong Liu, Yanping Ma, Da Gao, Wenhong Lai, Xin Zhou, Hongmei Jing, Jinqiao Zhang, Wei Yang, Xuehong Ran, Congmeng Lin, Jianping Hao, Taiwu Xiao, Zhenqian Huang, Zhigang Zhu, Qing Wang, Baijun Fang, Binghua Wang, Yanping Song, Zhen Cai, Bo Liu, Yanan Zhu, Xinai Yang, Xiaoyan Kang, Juan Li, Wenming Chen
This multicenter, open-label, single-arm trial (ClinicalTrials.gov, NCT05236621) was conducted to confirm the efficacy and safety of generic pomalidomide plus dexamethasone in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Total 79 eligible RRMM patients were planned to be included. Patients were treated with generic pomalidomide (4 mg daily on days 1-21, orally) and low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally; 20 mg for patients aged > 75 years) in 28-day cycles until disease progression with a maximum treatment duration of 2 years...
December 19, 2023: Annals of Hematology